| Literature DB >> 35676714 |
Vahid Mogharab1, Mahshid Ostovar2, Jakub Ruszkowski3,4, Syed Zohaib Maroof Hussain5, Rajeev Shrestha6, Uzair Yaqoob7, Poorya Aryanpoor2, Amir Mohammad Nikkhoo2, Parasta Heidari2, Athar Rasekh Jahromi2, Esmaeil Rayatdoost2, Anwar Ali8,9, Farshid Javdani2, Roohie Farzaneh10, Aref Ghanaatpisheh2, Seyed Reza Habibzadeh10, Mahdi Foroughian10, Sayyed Reza Ahmadi10, Reza Akhavan10, Bita Abbasi11, Behzad Shahi12, Arman Hakemi10, Ehsan Bolvardi10, Farhad Bagherian13, Mahsa Motamed14, Sina Taherzadeh Boroujeni14, Sheida Jamalnia15, Amir Mangouri16, Maryam Paydar2, Neda Mehrasa17, Dorna Shirali17, Francesco Sanmarchi18, Ayesha Saeed19, Narges Azari Jafari20, Ali Babou21, Navid Kalani22, Naser Hatami23.
Abstract
BACKGROUND: Apart from infecting a large number of people around the world and causing the death of many people, the COVID-19 pandemic seems to have changed the healthcare processes of other diseases by changing the allocation of health resources and changing people's access or intention to healthcare systems.Entities:
Keywords: COVID-19; Emergency department; Pandemic; SARS-COV-2
Mesh:
Year: 2022 PMID: 35676714 PMCID: PMC9175527 DOI: 10.1186/s12992-022-00836-2
Source DB: PubMed Journal: Global Health ISSN: 1744-8603 Impact factor: 10.401
PICO method for study questions
| PICO Evidence-based study concepts | Reference | |||||
|---|---|---|---|---|---|---|
| P: Population of interest | Emergencies in different ED consultations which needs a timely intervention | Neurology | Meningitis | Acute ischemic stroke | Seizures | [ |
| Cardiology | Acute MI/ Acute Coronary Ischemia | Aneurysm | Aortic Dissection | [ | ||
| Cardiac Tamponade | ||||||
| Nephrology | polyangiitis and Wegener’s granulomatosis | Nephrotic syndrome | [ | |||
| Gastroenterology | Upper GI bleeding | Lower GI bleeding | [ | |||
| Endocrinology | Diabetic ketoacidosis (DKA) | Hypoglycemia | Acute adrenocortical insufficiency | [ | ||
| Phaeochromocytoma crisis | Acute Hypercalcaemia | Thyroid storm | ||||
| Myxoedema coma | Acute pituitary apoplexy | |||||
| Rheumatology | Polyarteritis nodosa | polyarteritis nodosa | Scleroderma | [ | ||
| polyangiitis and Wegener’s granulomatosis | Catastrophic antiphospholipid syndrome | |||||
| General surgery | Acute abdominal conditions, including: | Respiratory obstruction, foreign bodies | [ | |||
| Incarcerated and Strangulated Inguinal Hernias | Bleeding from esophageal varices | |||||
| Appendicitis | Pelvic infections with abscesses | |||||
| Intestinal obstruction | Perforated typhoid ulcers | Surgical infections | ||||
| Complications of peptic ulcer | Amebic liver abscess | |||||
| Gall bladder and bile duct disease | ||||||
| Obstetrics & Gynecology | torsion of ovary | Ectopic Pregnancy | [ | |||
| pre-eclampsia and eclampsia | placenta praevia/placental abruption | Miscarriage | ||||
| premature rupture of membranes | ||||||
| Urology | Acute Scrotum (torsion of testis) | Acute Urinary Retention | Severe Hematuria | [ | ||
| Lithiasis | Fournier Gangrene | |||||
| Psychiatry | Suicide | Agitated and violent patients | [ | |||
| I: Intervention | Disease specific intervention in golden time | |||||
| C: Control | Pre-COVID-19 outcomes in same centers per study | |||||
| O: Outcome | Prevalence of Failure / Disruption of treatment, Prevalence of disease complications due to delayed care, Onset to hospital door time, Onset to treatment time, | |||||
Fig. 1Prisma Flow chart of study the National Institutes of Health (NIH) Quality Assessment Tool (Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies) was used to assess the quality of included studies and ranking studies in three categories of “good”, “fair”, and “poor”. (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
Characteristics of included studies
| Study ID | ref | Before the COVID-19 | During the COVID-19 | Country | relative changea | Quality | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| number of total cases | number of events | Time frame | number of total cases | number of events | Time frame | ||||||
| DKA rate in T1DM | Atlas al. | [ | 204 | 86 | 2020 | 58 | 30 | 2017–2019 | Australia | 0.81% | good |
| Ponmani al. | [ | 150 | 49 | January and July, 2020 | 178 | 79 | 2019 | UK | 1.03% | good | |
| Rabbone al. | [ | 208 | 86 | 2020 | 160 | 61 | 20 February and 14 April 2019 | Italia | 0.51% | good | |
| Kamrath et al. | [ | 959 | 233 | March 13 to May 13 2020 | 532 | 238 | 2019 and 2018 | Germany | 1.6% | good | |
| Bogale et al. | [ | 370 | 172 | 03/01/2020- and 09/14/2020 | 42 | 19 | 1/1/2017 to 2/28/2020 | USA | 0.51% | good | |
| Ho et al. | [ | 114 | 52 | March 17 to August 31, 2020 | 107 | 73 | 2019 | Canada | 1.04% | good | |
| Gera al. | [ | 31 | 13 | 2020 | 33 | 21 | 1 March to 30 June, 2019 | USA | 1.1% | fair | |
| Lawrence al. | [ | 42 | 11 | March to May,2020 | 11 | 8 | 2015–2019 | Australia | 2.51% | good | |
| Vassospasm rate in CT angiography | Fiorindi et al. | [ | 179 | 14 | March 9 to May 10, 2017–2018-2019 | 72 | 13 | March 9 to May 10, 2020 | Italy | 2.23% | fair |
| Aboukaïs et al. | [ | 28 | 21 | March 1st, 2019 and April 26th, 2019 | 26 | 24 | March 1st, 2019 and April 26th, 2020 | France | 0.48% | good | |
| Orchiectomy rate in testicular torsion | Nelson et al. | [ | 77 | 13 | 1 January 2018–29 February 2020 | 17 | 5 | 1 March 2020–31 May 2020 | USA | 1.57% | good |
| Littman et al. | [ | 47 | 21 | 2015 to 2019 | 20 | 5 | March 15, 2020 to May 4, 2020 | USA | 0.11% | good | |
| Pogorelić et al. | [ | 68 | 11 | January 1st, 2019 to March 10th, 2020 | 51 | 22 | March 11th, 2020 to December 31st, 2020 | Croatia | 2.5% | good | |
| Holzman et al. | [ | 137 | 40 | January 2019 through February 2020 | 84 | 34 | March through July 2020 | USA | 1.09% | good | |
| Lee et al. | [ | 55 | 18 | 3/11/2018 to 10/1/2019 | 27 | 12 | 3/11/2020 to 10/1/2020 | USA | 1.03% | good | |
| Shields | [ | 79 | 30 | March 1, 2015-December 31, 2019 | 38 | 19 | March 1, 2020-December 31, 2020 | USA | 0.94% | good | |
| rt-PA reciving rate in CVA patients | Xu et al. | [ | 153 | 53 | December 1, 2019, and January 30, 2020 | 99 | 29 | February 1, 2020, and March 31, 2020 | China | 0.5% | good |
| Velilla-Alonso et al. | [ | 112 | 65 | March 14 to May 14, 2019 | 83 | 36 | March 14 to May 14, 2020 | Spain | 0.17% | good | |
| Aref et al. | [ | 118 | 17 | whole study in December 7, 2019 and May 10, 2020; not clearly addresed | 136 | 31 | whole study in December 7, 2019 and May 10, 2020; not clearly addresed | Egypt | 1.44% | fair | |
| Roushdy. et al. | [ | 151 | 16 | February 15 to april 3, 2019 | 93 | 20 | February 15 to april 3, 2021 | Egypt | 1.92% | good | |
| Katsanos et al. | [ | 8 | March 17- april 30, 2019 | 12 | March 17- april 30, 2020 | Canada | fair | ||||
| Teo et al. | [ | 89 | 64 | January 23, 2020–March 24, 2019 | 73 | 40 | January 23, 2020–March 24, 2020 | Hong Kong | 0.04% | good | |
| Padmanabhan et al. | [ | 167 | 22 | March 15th and April 14th, 2019 | 101 | 11 | March 15th and April 14th, 2020 | UK | 0.69% | good | |
| D’Anna et al. | [ | 283 | 46 | 23rd March to 30th June 2019 | 235 | 27 | 23rd March to 30th June 2020 | UK | 0.54% | good | |
| Paliwal. et al. | [ | 206 | 25 | from 1st November 2019 to 7th February 2020 | 144 | 24 | from 7th February to 30th April 2020 | Singapore | 1.25% | good | |
| Tejada Meza et al. | [ | 492 | 178 | March 9–May 3, 2020 | 304 | 97 | December 30, 2019 - March 9, 2020 | Spain | 0.52% | good | |
| Agarwal et al. | [ | 634 | 195 | 6/1/2019–2/29/2020 | 120 | 38 | 03/012020–05/152020 | US | 0.72% | good | |
| Wallace et al. | [ | 2692 | 335 | Jan 1–Feb 29, 2020 | 1225 | 149 | Mar 20–Apr 25, 2020 | US | 0.85% | good | |
| Wu et al. | [ | 2354 | 1199 | 01/24/2019 to 04/29/2019 | 1281 | 791 | 01/24/2020 to 04/29/2020 | china | 0.7% | good | |
| Sevilis. et al. | [ | 15,226 | 1137 | December 1, 2019, to March 15, 2020 | 11,105 | 88 | March 15, 2020 to June 27, 2020 | US | 0.03% | good | |
| Tavanaei et al. | [ | 190 | 25 | 2019 (Mar 1 to Jun 1) | 95 | 18 | 2020 (Mar 1 to Jun 1) | Iran | 1.31% | good | |
| Srivastava et al. | [ | 39,113 | 4576 | November 1, 2019 and February 3, 2020 | 41,971 | 4785 | February 4, 2020 and June 29, 2020 | US | 0.86% | good | |
| Frisullo et al. | [ | 41 | 13 | March–April 2019 | 52 | 7 | March–April 2020 | Italy | 0.11% | fair | |
| Luo et al. | [ | 377 | 293 | January 2019 to May 2019 | 315 | 231 | January 2020 to May 2020 | China | 0.17% | good | |
| Bhatia et al. | [ | 1237 | 182 | February and July 2019 | 1312 | 230 | February and July 2020 | India | 1.04% | fair | |
| Cummings et al. | [ | 5239 | 656 | March 2019 to February 2020 | 613 | 95 | March to April 2020 | US | 1.11% | good | |
| Rinkel et al. | [ | 407 | 59 | October 21st–December 8th 2019 | 309 | 50 | March 16th–May 3th 2020 | Netherlands | 0.97% | good | |
| Ramos-Pachón et al. | [ | 1033 | 300 | March 15–May 2, 2020 | 805 | 177 | March 15–May 2, 2020 | Spain | 0.47% | good | |
| Meza et al. | [ | 225 | 52 | 30 December 2019 to 14 march, 2020 | 93 | 20 | 15 march, 2020 to 4 May 2020 | Spain | 0.7% | fair | |
| Velilla-Alonso et al. | [ | 112 | 65 | March 14 to May 14, 2019 | 83 | 36 | March 14 to May 14, 2020 | Spain | 0.17% | good | |
| Nagamine et al. | [ | 37 | 15 | March 1–April 30, 2019 | 36 | 10 | March 1–April 30, 2020 | US | 0.28% | good | |
| Siegler et al. | [ | 1491 | 124 | March 1, 2019, and July 31, 2019 | 1464 | 54 | March 1, 2020, and July 31, 2020 | US | 0.36% | good | |
| Wang et al. | [ | 320 | 20 | 12/1/19–03/11/20 | 255 | 30 | 03/12/20–06/30/20 | 1.82% | fair | ||
| Perforated appendicitis rate in acute appendicitis | Yang et al. | [ | 129 | 10 | January to September 209 | 106 | 19 | January to September 2020 | china | 0.25% | good |
| Zhou et al. | [ | 121 | 10 | 2019 | 81 | 15 | 2020 | china | 0.26% | good | |
| Tankel et al. | [ | 237 | 31 | 31 December 2019–18 February 2020 | 141 | 29 | 19 February 2020–07 April 2020 | Israel | 0.43% | good | |
| Orthopoulos et al. | [ | 199 | 50 | February 1–March 15, 2020/ 2019/ 2018 | 40 | 25 | March 16, 2020–April 30, 2020 | USA | −0.22% | good | |
| Kumaira Fonseca et al. | [ | 82 | 12 | March and April 2019 | 36 | 11 | March and April 2020 | Brazil | 0.17% | good | |
| Turanli et al. | [ | 145 | 31 | March 1st,2019–February 29th, 2020 | 59 | 12 | March 1st, 2020–May 31st, 2020 | Turkey | 0.85% | good | |
| Wang et al. | [ | 48 | 6 | January 21, 2018 to May 6, 2018, and January 21, 2019 to May 6, 2019 | 32 | 10 | January 2020 to May 2020 | USA | 0.09% | fair | |
| Jäntti et al. | [ | 127 | 22 | 1 February 2020 and 30 April 2020; first 6 weeks | 99 | 31 | 1 February 2020 and 30 April 2020; second 7 weeks | Finland | 0.24% | good | |
| Lisi et al. | [ | 34 | 9 | February 2019 and December 2019 | 27 | 16 | February 2020 and December 2020 | Italy | −0.15% | good | |
| Burgard et al. | [ | 241 | 37 | March 12 to June 6, 2017, 2018, and 2019 | 65 | 21 | March 12 to June 6, 2020 | switzerland | 0.15% | good | |
| Antakia et al. | [ | 110 | 22 | November 1, 2019 to March 10, 2020 | 59 | 12 | March 10, 2020 to July 5, 2020 | UK | 0.78% | good | |
| Finkelstein et al. | [ | 59 | 10 | March to May 2019 | 48 | 16 | March to May 2020 | USA | 0.18% | good | |
| Sartori et al. | [ | 791 | 76 | march-April 2019 | 546 | 87 | arch-April 2020 | Italy | 0.44% | good | |
| Baral et al. | [ | 42 | 6 | 90 prior March 24 2020 | 50 | 10 | 90 days after March 242,020 | Nepal | 0.51% | fair | |
| Toale et al. | [ | 122 | 11 | January 1st – March 25th | 62 | 13 | March 26th – May 31st | Ireland | 0.22% | good | |
| Dreifuss et al. | [ | 65 | 11 | April 1, 2020 and April 30, 2018, 2019 | 15 | 7 | April 1, 2020 and April 30, 2020 | Argentina | −0.1% | good | |
| Mor Aharoni et al. | [ | 60 | 5 | 1 March 2019 to 30 April 2019 | 74 | 0 | April 1, 2020 and April 30, 2020 | israel | NA | fair | |
| Neufeld et al. | [ | 840 | 181 | December 1, 2019–March 10, 2020 | 91 | 25 | March 11, 2020–May 16, 2020 | usa | 0.51% | good | |
| Scheijmans et al. | [ | 642 | 157 | February and March 2019 | 607 | 179 | February and March 2020 | Netherlands | 0.53% | good | |
| Somers et al. | [ | 69 | 4 | 12/03/2019 and 30/06/2019 | 40 | 8 | 12/03/2020 and 30/06/2020 | Ireland | 0.09% | good | |
| rupture rate in ectopic pregnancy | Barg et al. | [ | 43 | 2 | March 10–May 12, 2019 | 29 | 6 | March 10–May 12, 2020 | Israel | 0.02% | good |
| Dvash et al. | [ | 30 | 5 | 15 March and 15 June 2018, 2019 | 19 | 11 | 15 March and 15 June 2020 | Israel | −0.29% | good | |
| Toma et al. | [ | 136 | 82 | March 2019 and February 2020 | 62 | 50 | March 2020 and June 2020 | Delaware | −0.06% | fair | |
| Platts et al. | [ | 179 | 4 | January 2019–June 2019 | 162 | 3 | March 2020–August 2020 | UK | 1.19% | good | |
| Casadio et al. | [ | 201 | 52 | January 1st 2014 - February 29th 2020 | 9 | 6 | March 1st to 30th April 2020 | Italy | −0.28% | fair | |
| Anteby et al. | [ | 208 | 23 | February 27, 2020 to September 27, 2018, 2019 | 100 | 23 | February 27, 2020 to September 27, 2020 | Israel | 0.25% | good | |
| Werner et al. | [ | 12 | 51 | 2019–2020 | 10 | 12 | March 15th and May 17th, 2020 | USA | 2.34% | fair | |
| Dell’Utri et al. | [ | 9 | 20 | February 24 th - May 31 th 2019 | 11 | 16 | February 24 th - May 31 th 2020 | Italy | 0.07% | good | |
| ACS patient-related delay | Tam et al. | [ | 48 | – | February 1, 2018, to January 31, 2019 | 7 | – | January 25, 2020, to February 10, 2020 | China | NE | fair |
| Fileti et al. | [ | 94 | – | 10 March and 10 April 2019, | 72 | – | 10 March and 10 April 2020, | Italy | NE | good | |
| Mesnier et al. | [ | 664 | – | Feb to Mar 16 2020 | 457 | – | Mar 17 to Apri 122,020 | France | NE | good | |
| Choudhary et al. | [ | 1488 | – | (25 March to 24 April 2020 | 289 | – | (25 January to 24 February 2020 | India | NE | good | |
| Kwok et al. | [ | 33,255 | – | 1 January 2017 to 22 March 2020 | 683 | – | 23 March 2020 to 30 April 2020 | UK | NE | good | |
| Erol et al. | [ | 1872 | – | 15-day registry (November 1–15, 2018 | 991 | – | April 17–May 2, 2020 | Turkey | NE | good | |
| Erol (b) et al. | 1872 | – | 992 | – | NE | ||||||
| Toner et al. | [ | 102 | – | March 16–April 15 between 2014 and 2019 | 20 | – | March 16–April 15, 2020 | Australia | NE | good | |
| Li et al. | [ | 1092 | – | 2019 (Feb to Apr) | 1038 | – | 2020 (Feb to Apr) | Taiwan | NE | fair | |
| Claeys et al. | [ | 260 | – | March 13 to April 3 2019 | 188 | – | March 13 to April 32,019 | Belgium | NE | fair | |
| Trabattoni et al. | [ | 10 | – | March 8 and April 10,2019 | 24 | – | March 8 and April 10,2020 | Italy | NE | fair | |
| Braiteh et al. | [ | 113 | – | March/April of 2019 | 67 | – | March/April 2020 | USA | NE | good | |
| Cammalleri et al. | [ | 35 | – | Mar 1 to Mar 31 2019 | 13 | – | Mar 1 to Mar 31 2020 | Italy | NE | good | |
| Scholz et al. | [ | 1329 | – | Mar 2017–2019 | 387 | – | Mar2020 | Germany | NE | good | |
| Scholz (b) et al. | 1330 | – | 388 | – | NE | good | |||||
| Hauguel-Moreau et al. | [ | 63 | – | 2018–2019 from February 17 to April 26 | 16 | – | March 17, 2020 in France (week 12) | France | NE | good | |
| Romaguera et al. | [ | 524 | – | 1 March to 19 April 2019 | 395 | – | 1 March to 19 April, 2020 | Spain | NE | fair | |
| Romaguera (b) et al. | 525 | – | 396 | – | NE | ||||||
| Xiang et al. | [ | 626 | – | 4 weeks before January 24, 2020 | 236 | – | 4 weeks after January 24, 2020 | China | NE | good | |
| Xiang (b) et al. | 15,729 | – | 4 weeks before January 24, 2020 | 11,598 | – | 4 weeks after January 24, 2020 | non-hubai | NE | good | ||
| Yasuda et al. | [ | 274 | – | January–July 2015–2019 | 64 | – | January–July 2020 | Japan | NE | good | |
| Sutherland et al. | [ | 145 | – | 1 March 2020 to 31 April 2020 | 108 | – | 1 March 2020 to 31 April 2020 | Australia | NE | good | |
| Sutherland (b) et al. | 145 | – | 1 March 2020 to 31 April 2021 | 82 | – | 1 July 2020 to 31 August 2020 | Australia | NE | good | ||
| Trabattoni et al. | [ | 386 | – | Jan 1-Dec 31, 2019 | 599 | – | Jan 1-Dec 31, 2020 | Italy | NE | good | |
| Calvão et al. | [ | 80 | – | March and April 2019 | 71 | – | March and April 2020 | Portugal | NE | good | |
| Chan et al. | [ | 908 | – | 23 March – 26 April 2015–2019 | 164 | – | 23 March – 26 April 2020 | New Zealand | NE | good | |
| Nan et al. | [ | 158 | – | between August 1, 2019, and January 22, 2020 | 52 | – | January 23, 2020, and March 31, 2020 | China | NE | good | |
| Tomasoni et al. | [ | 51 | – | Jan 3 to Feb 20, 2020 | 34 | – | Feb 21 to Apr 10, 2020 | France | NE | good | |
aRelative change in event rate; NE not estimated
Meta-analysis results
| Panel | Outcome of interest | n | I | Estimate | P |
|---|---|---|---|---|---|
| CVA | symptoms onset to ED door time | 21 | 98.31% | DoM = 15.67 min, 95% CI:-22.84 to 54.18 | 0.4252 |
| rt-PA administration | 25 | 97.56% | RR = −0.11, 95% CI:-0.33 to 0.11 | 0.0914 | |
| ACS | symptom onset to first medical contacta | 12 | 99.52% | DoM = 65.71 min, 95% CI:-11.55 to 142.98 | 0.0955 |
| symptom onset to administration | 8 | 61.21% | DoM = 30.94 min, 95% CI:12.919 to 48.966 | 0.0008 | |
| aneurismal SAH | Vassospasm finding on CT angiography | 2 | 0.0% | RR = 1.575, 95% CI:0.72 to 2.42 | 0.003 |
| Fisher grade > 2 | 2 | 0.0% | RR = -0.0064, 95% CI: −0.2196 to 0.2068 | 0.9533 | |
| WFNS > 3 | 2 | 42.40% | RR = + 0.3088, 95% CI:-0.2631 0.8807 | 0.2899 | |
| Acute appendicitis | Perforated appendicitis | 20 | 18.59% | RR = + 0.362, 95% CI:0.2549 to 0.4690 | <.0001 |
| later than 72 hours ED visit | 3 | 75.32% | RR = + 0.641, 95% CI:-0.6104 to 1.8938 | 0.315 | |
| ectopic pregnancy | Rupture of ectopic pregnancy | 8 | 56.20% | RR = + 0.112, 95% CI:0.0248 to 0.201 trim and filled: RR = + 0.0670, 95% CI: −0.0064 to 0.1404 | trim and filled: 0.0734 |
| newly diagnosed T1DM | DKA presentation | 8 | 49.37% | RR = + 0.224, 95% CI:0.062 to 0.38 | 0.0065 |
| Testicular Torsion | Orchiectomy | 6 | 3% | RR = + 0.259, 95% CI:0.026 to 0.492 | 0.029 |
aPublication bias exist
Fig. 2Schematic of the relative change of different diseases after the pandemic. Relative change of (a) acute appendicitis, (b) ectopic pregnancy, (c) CVA, and (d) ACS incidence during COVID-19 pandemic